---
title: "Descartes-08 in Generalized myasthenia gravis: Limitations of current therapies"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Limitations of current therapies. Topics: Refractory disease despite conventional immunosuppression; Incomplete response to targeted biologics; Glucocorticoid toxicity and associated costs; Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors; 5 further topics. 10 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Limitations of current therapies

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

### Summary

- Refractory disease: Refractory MG has been defined as a post-intervention status unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning. An estimated 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and about 20,000 patients with generalized MG are estimated to be intolerant of or to have an inadequate response to conventional treatment.
- Incomplete response to targeted biologics: Upward of thirty percent of patients do not benefit from complement inhibition. No head-to-head prospective studies have compared the novel therapies; in one analysis, FcRn inhibitors carried greater odds of treatment-related adverse events than placebo (odds ratio 2.20 [1.52-3.38]), while C5 inhibitors and CD19+ B-cell depletion showed odds comparable to placebo.
- Glucocorticoid toxicity: Incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use and 52.3% of those without; common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection, and chronic toxicities included dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Toxicities and costs tended to increase with increasing glucocorticoid use.
- Infection risk and REMS: Eculizumab, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis, meningococcal vaccination is required at least 2 weeks before the first dose of eculizumab, and eculizumab and zilucoplan are available only through restricted REMS programs. One case of meningococcal meningitis occurred despite vaccination in the eculizumab open-label extension. In Study 1 of efgartigimod, urinary tract infections occurred in 10% of efgartigimod-treated and 5% of placebo-treated patients, and respiratory tract infections in 33% and 29%.
- Administration burden: Reported limitations include the need for meningococcal vaccination and regular intravenous or subcutaneous injections; eculizumab is infused intravenously over 35 minutes in adults, and the safety of starting rozanolixizumab cycles sooner than 63 days after the start of the previous cycle has not been established. Current targeted therapies generally require lifelong repeated administration and “rarely induce durable treatment-free remission”.
- Cost: In one cost-effectiveness analysis, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG. Very high drug costs have limited access to complement and FcRn inhibitors in most countries. Annual all-cause costs were $76,381 among patients with any glucocorticoid use and $35,309 among those without.

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/); [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/); [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/); [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf); [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf); [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/); [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf); [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf); [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.1.9-2"></a>

### Refractory disease despite conventional immunosuppression

> “Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Currently, it is estimated that about 20,000 patients with generalized MG are intolerant or have an inadequate response to conventional treatment options.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

<a id="topic-2.2.2.1.9-3"></a>

### Incomplete response to targeted biologics

> “There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.”
> “There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-4"></a>

### Glucocorticoid toxicity and associated costs

> “Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “although prednisone is still the most consistently effective drug for MG, its side effect burden and that of immunosuppressive as well as the poor response in a large minority”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-5"></a>

### Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors

> “SOLIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.”
> “Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of SOLIRIS”
> “Because of the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS.”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

> “One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.”
> “Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.9-6"></a>

### Infection risk with FcRn blockade

> “VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of VYVGART-treated patients compared to 5% of placebo-treated patients) and respiratory tract infections (33% of VYVGART-treated patients compared to 29% of placebo-treated patients)”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

### Administration burden: infusion schedules and repeated injections

> “Limitations include the need for meningococcal vaccination before starting treatment, pneumococcal vaccination which is recommended, and regular intravenous or subcutaneous injections.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Administer the SOLIRIS admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “The safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.9-8"></a>

### Cost and cost-effectiveness of targeted biologics

> “For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).”
> “The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

> “Very high drug costs have limited the accessibility to treatment in most countries.”
> “In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.9-9"></a>

### No head-to-head trials and higher odds of treatment-related adverse events with FcRn inhibitors

> “In the past decade, several novel therapies have shown promise in treating generalized myasthenia gravis (MG); however, no head-to-head prospective studies have compared their efficacy and safety.”
> “Patients treated with FcRn inhibitors had greater odds of treatment-related adverse events (odds ratio 2.20 [1.52-3.38]) compared with the placebo group, while C5i and CD19+ BCDT showed odds comparable to placebo.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.1.9-10"></a>

### Lifelong repeated administration of targeted therapies

> “Despite recent advances, current targeted therapies generally require lifelong repeated administration and rarely induce durable treatment-free remission.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
